Tobira Therapeutics (TBRA) PT Raised to $45 at Leerink

October 21, 2016 7:12 AM EDT
Get Alerts TBRA Hot Sheet
Price: $42.09 --0%

Rating Summary:
    3 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade TBRA Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and raised his price target on Tobira Therapeutics (NASDAQ: TBRA) to $45.00 (from $15.00) after late-breaking abstracts for the American Academy for the Study of Liver Diseases (AASLD) Meeting.

Schwartz commented, "TBRA is a pioneer in the nonalcoholic steatohepatitis (NASH) development space, and we believe that the current stock price somewhat undervalues the acquisition terms based on the most probable outcomes and contingent value rights' (CVR) conditions from Allergan (AGN, OP)."

For an analyst ratings summary and ratings history on Tobira Therapeutics click here. For more ratings news on Tobira Therapeutics click here.

Shares of Tobira Therapeutics closed at $40.18 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Definitive Agreement

Add Your Comment